These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31384314)

  • 21. Prospects of Disease-Modifying Osteoarthritis Drugs.
    Oo WM
    Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: A meta-analysis.
    Mathieu S; Tournadre A; Soubrier M; Sellam J
    Joint Bone Spine; 2022 Nov; 89(6):105444. PubMed ID: 35908643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
    Vrouwe JPM; Burggraaf J; Kloppenburg M; Stuurman FE
    Osteoarthr Cartil Open; 2021 Dec; 3(4):100212. PubMed ID: 36474768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging pharmaceutical therapies for osteoarthritis.
    Latourte A; Kloppenburg M; Richette P
    Nat Rev Rheumatol; 2020 Dec; 16(12):673-688. PubMed ID: 33122845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?
    Hellio Le Graverand-Gastineau MP
    Osteoarthritis Cartilage; 2009 Nov; 17(11):1393-401. PubMed ID: 19426849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis.
    Tenti S; Bruyère O; Cheleschi S; Reginster JY; Veronese N; Fioravanti A
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231158618. PubMed ID: 36937821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease.
    Roman-Blas JA; Bizzi E; Largo R; Migliore A; Herrero-Beaumont G
    Expert Opin Pharmacother; 2016 Sep; 17(13):1745-56. PubMed ID: 27326466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dehydroepiandrosterone and Experimental Osteoarthritis.
    Huang K; Wu LD; Bao JP
    Vitam Horm; 2018; 108():367-384. PubMed ID: 30029735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets.
    Le Graverand-Gastineau MP
    Curr Drug Targets; 2010 May; 11(5):528-35. PubMed ID: 20199396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hand osteoarthritis-nonpharmacological and pharmacological treatments.
    Kloppenburg M
    Nat Rev Rheumatol; 2014 Apr; 10(4):242-51. PubMed ID: 24468932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?
    Buttgereit F; Burmester GR; Bijlsma JW
    RMD Open; 2015; 1(1):e000027. PubMed ID: 26509057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on Novel Non-Operative Treatment for Osteoarthritis: Current Status and Future Trends.
    Chen T; Weng W; Liu Y; Aspera-Werz RH; Nüssler AK; Xu J
    Front Pharmacol; 2021; 12():755230. PubMed ID: 34603064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models.
    He Y; Li Z; Alexander PG; Ocasio-Nieves BD; Yocum L; Lin H; Tuan RS
    Biology (Basel); 2020 Jul; 9(8):. PubMed ID: 32751156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
    Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DMOAD developments: present and future.
    Pelletier JP; Martel-Pelletier J
    Bull NYU Hosp Jt Dis; 2007; 65(3):242-8. PubMed ID: 17922676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
    Oo WM; Little C; Duong V; Hunter DJ
    Drug Des Devel Ther; 2021; 15():2921-2945. PubMed ID: 34262259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What about strontium ranelate in osteoarthritis? Doubts and securities.
    Tenti S; Cheleschi S; Guidelli GM; Galeazzi M; Fioravanti A
    Mod Rheumatol; 2014 Nov; 24(6):881-4. PubMed ID: 24645726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases.
    Song Z; Li Y; Shang C; Shang G; Kou H; Li J; Chen S; Liu H
    Front Cell Dev Biol; 2021; 9():786546. PubMed ID: 34970547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Contributions to Osteoarthritis.
    Lopes EBP; Filiberti A; Husain SA; Humphrey MB
    Curr Osteoporos Rep; 2017 Dec; 15(6):593-600. PubMed ID: 29098574
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.